The development of live attenuated cold-adapted influenza virus vaccine for humans

Development of an Attenuated Live Virus Vaccine against Sheep Pox

Development of Cold-adapted Recombinant Live, Attenuated Influenza a Vaccines in the U.s.a. and U.s.s.r

Influenza remains a major public health problem in many countries. Periodic epidemics disrupt economic and social activities within entire communities, impose sudden large demands on available medical facilities, and can cause excess mortality, particularly in the elderly or those with certain chronic illnesses [5,7,21]. Vaccination can provide significant protection against infection and illne...

Adverse events reported following live, cold-adapted, intranasal influenza vaccine.

CONTEXT In June 2003, the US Food and Drug Administration licensed a trivalent live, attenuated influenza vaccine (LAIV-T) for intranasal administration to healthy persons 5 to 49 years of age. Although prelicensure testing involved 20 228 vaccinees, clinical trials were not of sufficient size to detect rare adverse events reliably. OBJECTIVE To identify adverse events reported following LAIV...

Development of a New Live Attenuated Mumps Virus Vaccine in Human Deploid Cells

Pan-Influenza A Protection by Prime–Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model

Influenza virus infections continually pose a major public health threat with seasonal epidemics and sporadic pandemics worldwide. While currently licensed influenza vaccines provide only strain-specific protection, antigenic drift and shift occasionally render the viruses resistant to the host immune responses, which highlight the need for a vaccine that provides broad protection against multi...